| Dr Neil Stuart Horowitz, MD | |
|
75 Francis St, Brigham And Women's Hospital, Boston, MA 02115-6110 | |
| (617) 732-8843 | |
| (617) 738-5124 |
| Full Name | Dr Neil Stuart Horowitz |
|---|---|
| Gender | Male |
| Speciality | Gynecological Oncology |
| Experience | 28 Years |
| Location | 75 Francis St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629050919 | NPI | - | NPPES |
| 2011026 | Medicaid | MA | |
| 217409 | Other | MA | TUFTS HEALTH PLAN |
| J26246 | Other | MA | BCBS MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 217409 (Massachusetts) | Primary |
| 207VX0201X | Obstetrics & Gynecology - Gynecologic Oncology | 217409 (Massachusetts) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Milford Regional Medical Center | Milford, MA | Hospital |
| Newton-wellesley Hospital | Newton, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brigham And Women's Physicians Organization Inc | 3870405988 | 2510 |
| Milford Regional Physician Group, Inc. | 5597679449 | 233 |
| Dana-farber Cancer Institute, Inc. | 9133038904 | 538 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).
A biochemical alteration that has long been viewed as an adverse aspect of tumor biology may turn out to be a deadly double-edged sword for the cancer cells themselves.
Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Vycor Medical, Inc., a medical device company that designs, develops and markets next generation neurosurgery retraction devices, today announced its ViewSite Brain Access System (VBAS) medical retraction device continues to gain ground. This "BioTech Breakthrough" - with the potential to impact several hundreds of thousands of patients and throngs of surgeons and medical facilities worldwide - is among a pioneering new breed of cost-reducing surgical devices designed to enhance performance, quality of life and surgical results.
Stage III colon cancer patients in the general population who receive adjuvant treatment for the disease have an improved rate of survival when oxaliplatin is added to 5-fluorouracil (5FU), according to a study published Jan. 20 in the Journal of the National Cancer Institute.
› Verified 4 days ago
| Entity Name | Dana-farber Cancer Institute, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851333686 PECOS PAC ID: 9133038904 Enrollment ID: O20040223000228 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).
A biochemical alteration that has long been viewed as an adverse aspect of tumor biology may turn out to be a deadly double-edged sword for the cancer cells themselves.
Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Vycor Medical, Inc., a medical device company that designs, develops and markets next generation neurosurgery retraction devices, today announced its ViewSite Brain Access System (VBAS) medical retraction device continues to gain ground. This "BioTech Breakthrough" - with the potential to impact several hundreds of thousands of patients and throngs of surgeons and medical facilities worldwide - is among a pioneering new breed of cost-reducing surgical devices designed to enhance performance, quality of life and surgical results.
Stage III colon cancer patients in the general population who receive adjuvant treatment for the disease have an improved rate of survival when oxaliplatin is added to 5-fluorouracil (5FU), according to a study published Jan. 20 in the Journal of the National Cancer Institute.
› Verified 4 days ago
| Entity Name | Milford Regional Physician Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902856024 PECOS PAC ID: 5597679449 Enrollment ID: O20040503001341 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).
A biochemical alteration that has long been viewed as an adverse aspect of tumor biology may turn out to be a deadly double-edged sword for the cancer cells themselves.
Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Vycor Medical, Inc., a medical device company that designs, develops and markets next generation neurosurgery retraction devices, today announced its ViewSite Brain Access System (VBAS) medical retraction device continues to gain ground. This "BioTech Breakthrough" - with the potential to impact several hundreds of thousands of patients and throngs of surgeons and medical facilities worldwide - is among a pioneering new breed of cost-reducing surgical devices designed to enhance performance, quality of life and surgical results.
Stage III colon cancer patients in the general population who receive adjuvant treatment for the disease have an improved rate of survival when oxaliplatin is added to 5-fluorouracil (5FU), according to a study published Jan. 20 in the Journal of the National Cancer Institute.
› Verified 4 days ago
| Entity Name | Brigham And Women's Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033535497 PECOS PAC ID: 3870405988 Enrollment ID: O20150107001260 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).
A biochemical alteration that has long been viewed as an adverse aspect of tumor biology may turn out to be a deadly double-edged sword for the cancer cells themselves.
Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Vycor Medical, Inc., a medical device company that designs, develops and markets next generation neurosurgery retraction devices, today announced its ViewSite Brain Access System (VBAS) medical retraction device continues to gain ground. This "BioTech Breakthrough" - with the potential to impact several hundreds of thousands of patients and throngs of surgeons and medical facilities worldwide - is among a pioneering new breed of cost-reducing surgical devices designed to enhance performance, quality of life and surgical results.
Stage III colon cancer patients in the general population who receive adjuvant treatment for the disease have an improved rate of survival when oxaliplatin is added to 5-fluorouracil (5FU), according to a study published Jan. 20 in the Journal of the National Cancer Institute.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Neil Stuart Horowitz, MD 111 Cypress St, Brookline, MA 02445-6002 Ph: (857) 307-0896 | Dr Neil Stuart Horowitz, MD 75 Francis St, Brigham And Women's Hospital, Boston, MA 02115-6110 Ph: (617) 732-8843 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).
A biochemical alteration that has long been viewed as an adverse aspect of tumor biology may turn out to be a deadly double-edged sword for the cancer cells themselves.
Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Vycor Medical, Inc., a medical device company that designs, develops and markets next generation neurosurgery retraction devices, today announced its ViewSite Brain Access System (VBAS) medical retraction device continues to gain ground. This "BioTech Breakthrough" - with the potential to impact several hundreds of thousands of patients and throngs of surgeons and medical facilities worldwide - is among a pioneering new breed of cost-reducing surgical devices designed to enhance performance, quality of life and surgical results.
Stage III colon cancer patients in the general population who receive adjuvant treatment for the disease have an improved rate of survival when oxaliplatin is added to 5-fluorouracil (5FU), according to a study published Jan. 20 in the Journal of the National Cancer Institute.
› Verified 4 days ago
Sheela S Maru, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 850 Harrison Ave, Yacc 4, Boston, MA 02118 Phone: 617-414-2000 Fax: 617-414-5798 | |
Dr. Devon Abt Harris, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 330 Brookline Ave # Shapiro8, Boston, MA 02215 Phone: 617-667-3736 Fax: 617-667-7493 | |
Maureen E Paul, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1055 Commonwealth Ave, Boston, MA 02215 Phone: 917-208-9521 | |
Charles-chidi W Obasiolu, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Ctr For Fertility & Repro Hlth, 133 Brookline Ave, Boston, MA 02215 Phone: 617-421-2987 Fax: 617-421-2989 | |
Dr. Erik M Clinton, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 750 Washington St, Boston, MA 02111 Phone: 617-636-5000 | |
Evelyn Hall, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Boston, MA 02111 Phone: 269-552-8685 | |
Toni Beth Walzer, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 333 Longwood Avenue, Adolescent Gynecology, Boston, MA 02115 Phone: 617-355-5785 |